| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6487312 | Current Opinion in Biotechnology | 2018 | 7 Pages |
Abstract
- Many omics-based tests are proposed in the literature but very few make it to the clinic.
- First two multiplexed tests using selective reaction monitoring (SRM-MS) mass spectrometry in the blood have entered clinical practice.
- Development of both tests used the same strategy from discovery through clinical use.
- This strategy succeeded in two different applications: lung cancer and pre-term birth.
- We present here that strategy as a roadmap for development of future tests for other indications.
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
Paul Kearney, J Jay Boniface, Nathan D Price, Leroy Hood,